Shares of Ocular Therapeutix, Inc. (OCUL) fell sharply on Tuesday morning even after the company reported positive Phase 3 trial results for its investigational wet age-related macular degeneration (AMD) therapy.
The stock is currently trading at $6.86, down $2.03 or 22.80%, on the Nasdaq. The stock opened at $6.41 after closing Monday at $8.88. The stock has traded between $5.78 and $16.44 in the past 52-week period.
Ocular Therapeutix reported that its Phase 3 SOL-1 superiority trial met its primary endpoint with high statistical significance, showing that AXPAXLI outperformed aflibercept in patients with wet AMD. The therapy also demonstrated strong durability and reduced treatment burden.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.